Article
UPDATED: The disruptors at EQRx have their eyes on the PD-(L)1 market — teeing up $150M cash to g
Rating:
0.0
Views:
117
Likes:
1
Library:
1
EQRx is paying top dollar to bring a pair of PD-(L)1 drugs into its portfolio of fast-follow therapies, offering $150 million upfront in what could shape up to be a $1.3 billion alliance with China's CStone. As early as 2017 Celgene had bet on a made-in-China PD-1 via its pact
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value